SCHEMBL6860607

SCHEMBL6860607

COC(=O)c1ccc(COc2cc(Cl)ccc2N(C(C)C)S(=O)(=O)c2ccccc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.47
LMNA P02545 2/20 0.47
MEN1 O00255 1/20 0.47
GAA P10253 1/20 0.47
KMT2A Q03164 1/20 0.47
KEAP1 Q14145 5/20 0.47
NFE2L2 Q16236 5/20 0.47
KDM4E B2RXH2 3/20 0.46
ALDH1A1 P00352 2/20 0.46
RAB9A P51151 2/20 0.43
NPC1 O15118 1/20 0.43
HPGD P15428 2/20 0.43
HTT P42858 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
PSEN1 P49768 2/20 0.43
PSEN2 P49810 2/20 0.43
APH1B Q8WW43 2/20 0.43
NCSTN Q92542 2/20 0.43
APH1A Q96BI3 2/20 0.43
PSENEN Q9NZ42 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1138787 0.92 MAPT (0.47) MAPTLMNAMEN1GAAKMT2A
SCHEMBL6864347 0.91 MRGPRX4 (0.52) MAPTLMNAMEN1KMT2AKEAP1
SCHEMBL6864195 0.89 KEAP1 (0.54) MAPTLMNAMEN1GAAKMT2A
SCHEMBL27490796 0.88 PSEN1 (0.47) KEAP1NFE2L2PSEN1PSEN2APH1B
SCHEMBL6860515 0.86 KEAP1 (0.50) MAPTLMNAMEN1GAAKMT2A
SCHEMBL6861447 0.85 KEAP1 (0.47) KEAP1NFE2L2
SCHEMBL1138751 0.83 MRGPRX4 (0.55) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL6861217 0.83 AKR1C3 (0.49) LMNAKEAP1NFE2L2KDM4EALDH1A1
SCHEMBL6861220 0.83 AKR1C3 (0.49) LMNAKEAP1NFE2L2KDM4EALDH1A1
SCHEMBL27507356 0.82 KEAP1 (0.47) MAPTMEN1KMT2AKEAP1NFE2L2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1213019-C Sulfonamide and carboxamide derivatives and drugs containing same as active ingredient ONO PHARMACEUTICAL CO (JP) 2005-08-03 CN disclosed
US-6790866-B2 SUCH AS 4-(2-PHENYLSULFONYLAMINO-5-CHLOROBENZOYLAMINO)BENZOIC ACID FOR USE AS PROSTAGLANDIN E2 ANTAGONIST OR AGONIST; FOR INHIBITION OF UTERINE CONTRACTION, ANALGESICS, ANTIDIARRHEALS, SLEEP INDUCERS, AND/OR FOR INCREASE OF VESICAL CAPACITY ONO PHARMACEUTICAL CO., LTD. (JP) 2004-09-14 US disclosed
US-20030060460-A1 Such as 4-(2-phenylsulfonylamino-5-chlorobenzoylamino)benzoic acid for use as prostaglandin E2 antagonist or agonist; for inhibition of uterine contraction, analgesics, antidiarrheals, sleep inducers, and/or for increase of vesical capacity OHUCHIDA SHUICHI (JP) 2003-03-27 US disclosed
US-6448290-B1 PROSTAGLANDIN E2 ANTAGONIST OR AGONIST; INHIBITION OF UTERINE CONTRACTION, ANALGESICS, ANTIDIARRHEALS, SLEEP INDUCERS, INCREASING VESICAL CAPACITY, CATHARTIC, SUPPRESSION OF GASTRIC ACID SECRETION, ANTIHYPERTENSIVE, DIURETIC AGENTS ONO PHARMACEUTICAL CO., LTD. (JP) 2002-09-10 US disclosed
CN-1247529-A Sulfonamide and carboxamide derivatives and drugs containing same as active ingredient ONO PHARMACEUTICAL CO (JP) 2000-03-15 CN disclosed
EP-0947500-A1 SULFONAMIDE AND CARBOXAMIDE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 1999-10-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030060460-A1 Such as 4-(2-phenylsulfonylamino-5-chlorobenzoylamino)benzoic acid for use as prostaglandin E2 antagonist or agonist; for inhibition of uterine contraction, analgesics, antidiarrheals, sleep inducers, and/or for increase of vesical capacity CNR1, HCAR1, HCAR2 MAPT 4870/4885LMNA 2967/4885MEN1 4832/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.